Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
END: Early Neutropenic Fever De-escalation Study
NCT06278896Phase 3Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2026
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Mortality, transfer to the ICU, septic shock, culture-confirmed bacteremia at 60 days and Antibiotic utilization at 60 days. Planned start Mar 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06278896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278896.